TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hemostemix ( (TSE:HEM) ) just unveiled an update.
Hemostemix announced its participation in DFCon 2025, a leading conference on diabetic foot care, where it will showcase its stem cell therapy, VesCell, which has shown promising results in reducing mortality and preserving limbs in diabetic patients. Additionally, Hemostemix closed a non-brokered private placement of $518,440, which will support its ongoing operations and potentially enhance its market position in the stem cell therapy industry.
Spark’s Take on TSE:HEM Stock
According to Spark, TipRanks’ AI Analyst, TSE:HEM is a Neutral.
Hemostemix’s stock is primarily hindered by its poor financial performance, characterized by no revenue and high leverage. The technical analysis points to positive momentum, but valuation concerns due to negative earnings are significant. The absence of earnings call data and impactful corporate events limits further insights.
To see Spark’s full report on TSE:HEM stock, click here.
More about Hemostemix
Hemostemix is an autologous stem cell therapy platform company founded in 2003. It has developed and patented VesCell (ACP-01), a blood-based stem cell therapy, and has completed seven clinical studies with results published in eleven peer-reviewed journals. The company focuses on treatments for peripheral arterial disease, chronic limb-threatening ischemia, and other cardiovascular conditions.
Average Trading Volume: 114,552
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$16.02M
Learn more about HEM stock on TipRanks’ Stock Analysis page.